IceCure Medical (NASDAQ:ICCM – Get Free Report) and Bausch + Lomb (NYSE:BLCO – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.
Volatility and Risk
IceCure Medical has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500.
Profitability
This table compares IceCure Medical and Bausch + Lomb’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IceCure Medical | -427.67% | -174.26% | -112.58% |
| Bausch + Lomb | -2.05% | 5.01% | 2.34% |
Analyst Recommendations
This is a breakdown of recent ratings for IceCure Medical and Bausch + Lomb, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IceCure Medical | 1 | 1 | 2 | 0 | 2.25 |
| Bausch + Lomb | 1 | 8 | 4 | 2 | 2.47 |
IceCure Medical presently has a consensus target price of $30.00, indicating a potential upside of 3,926.85%. Bausch + Lomb has a consensus target price of $20.83, indicating a potential downside of 1.18%. Given IceCure Medical’s higher possible upside, analysts clearly believe IceCure Medical is more favorable than Bausch + Lomb.
Insider & Institutional Ownership
0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares IceCure Medical and Bausch + Lomb”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IceCure Medical | $3.95 million | 0.65 | -$15.06 million | ($8.52) | -0.09 |
| Bausch + Lomb | $5.42 billion | 1.39 | -$360.00 million | ($0.31) | -68.01 |
IceCure Medical has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Bausch + Lomb beats IceCure Medical on 10 of the 15 factors compared between the two stocks.
About IceCure Medical
IceCure Medical Ltd. is an Israel-based medical technology company that develops and commercializes minimally invasive cryoablation systems. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, offering a percutaneous approach to treating tumors. The company’s ProSense system is designed for image-guided cryoablation and is used in procedures involving breast, kidney, lung, bone and other tumors. IceCure also offers the IceSense3 system for treating benign breast fibroadenomas.
About Bausch + Lomb
Bausch + Lomb Corporation is an eye-health company that develops, manufactures and markets products for consumers, eye-care professionals and surgical teams. Its business spans vision care, pharmaceuticals and surgical devices. Its products include contact lenses and lens-care solutions, as well as eye-health medicines and nutritional supplements. The company also supplies equipment, technologies and related products used in eye surgery and other ophthalmic procedures. Founded in Rochester, New York, in 1853 by John Jacob Bausch and Henry Lomb, the company serves customers in more than 100 countries.
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
